As envisioned by Minpromtorg, it has to occur in 2019. Now the country completely depends on deliveries from abroad which stopped being stable: The Moscow endocrine plant was announced problems by the Employee of production laboratory of the Moscow endocrine plant. Photo: Sergey of Savostyanov/TASS Minpromtorg did not obtain information on refusal of Great Britain to deliver to the Moscow endocrine plant opium substances for production of anesthetics, reported to TASS in the press service of the ministry. Earlier such refusal was announced by the CEO of the above-mentioned plant Mikhail Fonaryov. Against the background of these cautions a talk that to grow up opium poppy for medicine appeared again can resolve also in Russia. According to Minpromtorg, the relevant bill is already introduced in the government. The ministry expects that in 2019 it will be possible to pass to domestic substances for opioid anesthetics. Experts see direct link. At the moment Russia buys 100% of substances for production of narcotic drugs. In the country cultivation of opium poppy is forbidden. The Moscow endocrine plant which announced problems with deliveries — one of the producers of narcotic anesthetics, largest in the country. As the director Mikhail Fonaryov said it, "now we completely depend on supply of opium substances from other countries imposing sanctions against Russia". "We buy morphines, codeines from Spain and Great Britain. The last refused deliveries" — he noted. Prichin Fonaryov did not call. According to experts even if it so, it would be possible to reorient purchases and on other countries. But Fonaryov insists: import substitution is necessary. For this purpose, according to him, about 200 hectares are necessary for cultivation of opium plants and the amendment to the law. And here in Minpromtorg report that the relevant initiatives already got approval from profile departments. It is difficult to consider disturbing applications of Fonaryov out of a context, the CEO of the analytical agency DSM Group Sergey Shulyak considers: Sergey Shulyak the CEO of the analytical agency DSM Group "A question rose the same Moscow endocrine plant one and a half years ago, and now documents are ready, and, most likely, this information the throw is attempt to create information background for the purpose of acceleration and giving of importance to adoption of these documents. Of course, relationship between the Moscow endocrine plant and their suppliers is their commercial relationship that does not cancel, of course, a possibility of development of own production in Russia". According to the expert, import substitution in this area is really necessary. There is even such opinion: these measures will allow to reduce prices of medicines by 15-20%. However, the director of Institute of economy of health care of Higher School of Economics National Research University Larissa Popovic does not agree with it: Larissa Popovic the director of Institute of economy of health care of Higher School of Economics National Research University "As for reduction of prices, unfortunately, so far experience of localization shows that it not always occurs. In усл
From Astana to Nursultan — one step
Date: 2019-03-22 05:002 hrs ago
The authorities of Kazakhstan approved renaming of the capital. However it became clear that this decision not all citizens Astana support, Kazakhstan. Photo: the parliament of Kazakhstan approved by...
View details »
Volvo cars will operate drivers
Date: 2019-03-21 22:009 hrs ago
At the beginning of the 2020th years the company plans to introduce in the cars systems for control of drivers. Before Volvo decided to limit the speed of the cars to 180 kilometers per hour of the Ph...
View details »